Skip to main content
. 2018 May 25;9(40):25957–25970. doi: 10.18632/oncotarget.25409

Figure 5. Pathways altered in brain metastases compared to primary NSCLC.

Figure 5

(A) the PI3K/AKT and JAK/STAT signaling pathways and (B) the DNA Damage Response pathway. Red = gain of function, Blue = loss of function; Gray = inferred normal. Entities outlined in red are potential drug targets.